APOA5 and hypertriglyceridemia: Collectively, although the genetic variants of CETP might affect the efficacy of statins to reduce cardiovascular risk, and the variants of APOA5 may be associated with hypertriglyceridemia, further studies are needed to elucidate the exact meaning of the findings in this study.